IBA launches Cyclone® iKure, a cyclotron designed for industrial scale Astatine-211 production
Louvain-la-Neuve, Belgium – 01 June 2026 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the leading provider of radiopharmaceutical production solutions, today launches Cyclone® iKure, a dedicated cyclotron for routine Astatine-211 (At-211) production. Designed for alpha-beam irradiation, this new cyclotron enables radiopharmaceutical manufacturers, research institutions and healthcare providers to accelerate access to targeted alpha therapi
Louvain-la-Neuve, Belgium – 01 June 2026 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the leading provider of radiopharmaceutical production solutions, today launches Cyclone® iKure, a dedicated cyclotron for routine Astatine-211 (At-211) production. Designed for alpha-beam irradiation, this new cyclotron enables radiopharmaceutical manufacturers, research institutions and healthcare providers to accelerate access to targeted alpha therapies with the reliability and quality required for clinical-scale programs.
Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.